Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Hosp Infect ; 86(2): 110-6, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24412643

ABSTRACT

BACKGROUND: The incorrect use of clinical gloves and the failure to change them between procedures increases the risk of cross-transmission. Much attention has been focused on compliance with hand hygiene. AIM: To investigate the use of gloves, their potential for cross-contamination, and factors that influence the decision of healthcare workers (HCWs) to wear them. METHODS: The use of gloves was observed in six wards in a single UK hospital trust. Risk of cross-contamination was defined as a violation of a 'moment of hand hygiene' during the glove-use episode. Twenty-five HCWs from the wards included in the observational audit were interviewed to identify the drivers for glove use. FINDINGS: A total of 163 glove-use episodes were observed over a period of 13 h. Glove use was inappropriate in 69 out of 163 (42%) episodes, with gloves commonly used inappropriately for low-risk procedures (34/37; 92%). In 60 out of 163 (37%) episodes of glove use there was a risk of cross-contamination, most (48%) being associated with failure to remove gloves or with performing hand hygiene after use. HCW interviews indicated that the decision to wear gloves was influenced by both socialization and emotion. Key emotions were disgust and fear. Assumptions that patients preferred gloves to be used, confusion about when to wear them, and social norms and peer pressure were also important influences. CONCLUSION: Glove use is associated with risk of cross-contamination and should be more explicitly integrated into hand hygiene policy. An understanding of the drivers of glove-use behaviour is required to design interventions to reduce misuse and overuse.


Subject(s)
Attitude of Health Personnel , Cross Infection/prevention & control , Gloves, Protective/statistics & numerical data , Health Personnel , Hospitals , Humans , United Kingdom
2.
Neurosci Lett ; 313(3): 145-8, 2001 Nov 09.
Article in English | MEDLINE | ID: mdl-11682148

ABSTRACT

Neuropeptide FF (NPFF) is a mammalian peptide that is found in high concentrations in the central nervous system (CNS) and has also been detected in plasma. Various functions have been attributed to this peptide although its main action in the CNS remains unclear. In this study we observed that intracerebroventricular (ICV) injection of human NPFF, at early light phase in fasted rats, acutely reduced food intake and caused a large increase in water intake compared with saline injected controls. This effect was independently observed in two separate studies yielding similar results. Thus the central effects of NPFF to decrease food intake may be largely attributable to increased water intake.


Subject(s)
Drinking/drug effects , Eating/drug effects , Immediate-Early Proteins , Narcotic Antagonists/administration & dosage , Oligopeptides/administration & dosage , Animals , Behavior, Animal/drug effects , Brain/drug effects , Brain/metabolism , DNA-Binding Proteins/metabolism , Dose-Response Relationship, Drug , Early Growth Response Protein 1 , Humans , Injections, Intraventricular , Male , Motor Activity/drug effects , Proto-Oncogene Proteins c-fos/metabolism , Rats , Rats, Wistar , Reaction Time , Time Factors , Transcription Factors/metabolism
3.
Blood ; 80(2): 420-8, 1992 Jul 15.
Article in English | MEDLINE | ID: mdl-1627800

ABSTRACT

The response of megakaryocytes and platelets to the administration of recombinant human interleukin-6 (IL-6) was investigated in normal and sublethally irradiated dogs. IL-6 was administered for 2 weeks at doses of 10 to 160 micrograms/kg/d to normal animals to assess dose-response and toxicity. Subsequently, 40, 80, or 160 micrograms/kg/d for 2 weeks was administered to animals treated with 200 cG total body irradiation. Analysis of normal dogs showed a significant increment in the platelet count detectable approximately 11 days after initiation of IL-6 at all administered doses. Large platelets greater than 6.3 microns in diameter were observed 1 day after beginning IL-6, progressively increasing to as many as 19.1% of the total circulating platelets by day 10. The ploidy distribution of the marrow megakaryocytes did not differ from the normal at doses of less than or equal to 80 micrograms/kg/d, but at 160 micrograms/kg/d, a shift toward higher ploidy cells was noted. No change in total white count was noted; however, a decrease in hematocrit was seen at all doses. In the irradiated animals, the platelet count recovered earlier in the IL-6-treated dogs than in the controls, but no consistent change in the ploidy distribution was observed irrespective of dose. Large platelets were also noted in the treated animals, comprising up to 6.9% of the total platelet count. Fibrinogen levels were elevated to greater than 4 times normal. A significant decrease in hematocrit was seen in all animals, while no consistent change was noted in the white count. Elevations in serum cholesterol, triglycerides, and alkaline phosphatase, together with a decline in serum albumin were observed in all the treated animals (both normal and irradiated), but clinical symptoms were observed only in the dogs receiving greater than or equal to 80 micrograms/kg/d. The data show that IL-6 alone is capable of enhancing platelet recovery in dogs with bone marrow suppression.


Subject(s)
Blood Platelets/drug effects , Hematopoiesis/drug effects , Interleukin-6/pharmacology , Platelet Count/drug effects , Animals , Blood Platelets/cytology , Blood Platelets/radiation effects , Bone Marrow/drug effects , Bone Marrow/radiation effects , Bone Marrow Cells , Dogs , Fibrinogen/metabolism , Hematopoiesis/radiation effects , Interleukin-6/blood , Kinetics , Platelet Count/radiation effects , Ploidies , Recombinant Proteins/pharmacology , Time Factors , Whole-Body Irradiation
SELECTION OF CITATIONS
SEARCH DETAIL
...